Insulin Deprivation on Brain Structure and Function in Humans With Type 1 Diabetes

Sponsor
Mayo Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT03392441
Collaborator
(none)
28
1
1
19.1
1.5

Study Details

Study Description

Brief Summary

What are the effects of transient insulin deprivation on brain structure, blood flow, mitochondrial function, and cognitive function in T1DM patients?

What are the effects of transient insulin deprivation on circulating exosomes and metabolites in T1DM patients?

Condition or Disease Intervention/Treatment Phase
  • Other: Insulin Deprivation in Type 1 Diabetic Patients
N/A

Detailed Description

Diabetes is associated with impaired cognition, abnormal brain development in children, and dementia in older adults, however the underlying mechanisms remain unclear. Little is known about the brain-specific effects of acute insulin deficiency. Our recent studies in diabetic mice show an overall down regulation of brain mitochondrial ATP production and up regulation of several key mitochondrial proteins, indicating that insulin withdrawal has a profound effect on brain mitochondria as well as proteins implicated in neurodegeneration. Hyperglycemia is known to alter cognitive function, but it is unclear if insulin deprivation independently alters cognitive function and has not been assessed in humans.

In order to investigate the effects of insulin deprivation on the human brain, we propose a study involving temporary insulin deprivation in adolescents and adults with type 1 diabetes (T1DM). We will perform brain MRI, phosphorus31 spectroscopy, cognitive testing, circulating blood exosome measurements, and proteomics from muscle biopsy; comparing these measures during insulin treatment and deprivation between diabetic patients and age-, sex-, BMI-matched controls.

Specific aim 1: Determine whether transient insulin deprivation in T1DM adults and adolescents alters brain structure, functions and blood flow as assessed by structural/functional MRI.

Specific aim 2: Determine whether transient insulin deprivation in T1DM adults and adolescents alters cognitive function.

Specific aim 3: Determine whether transient insulin deprivation in T1DM adults and adolescents alters the circulating blood exosome contents and metabolome that can potentially impact brain functions.

Specific aim 4: Determine whether transient insulin deprivation in T1DM adults alters the skeletal muscle proteome homeostasis especially those involved in fission and fusion

Study Design

Study Type:
Interventional
Actual Enrollment :
28 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Pilot Study to Evaluate the Effects of Insulin Deprivation on Brain Structure and Function in Humans With Type 1 Diabetes
Actual Study Start Date :
Nov 30, 2017
Actual Primary Completion Date :
Aug 1, 2018
Actual Study Completion Date :
Jul 5, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Insulin Deprivation

Insulin Deprivation in Type 1 Diabetic Patients will be performed for a short time period (4-6 hours). Changes to Age, Sex, and Gender matched controls will be compared.

Other: Insulin Deprivation in Type 1 Diabetic Patients
Type 1 Diabetic Patients requiring insulin will have insulin stopped for a short period of time (4-6 hours)

Outcome Measures

Primary Outcome Measures

  1. Change in Structural MRI [baseline, 6 hours]

    Structural magnetic resonance imaging (MRI) is a non-invasive technique for examining the anatomy and pathology of the brain (as opposed to using functional magnetic resonance imaging [fMRI] to examine brain activity. This produces images which can be used for clinical radiological reporting as well as for detailed analysis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
14 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria:
  • Male and females age 14-17 years, females must be post-menarcheal

  • Age 18-45 years

  • Able to provide written consent

  • Parents able to provide written consent

  • T1DM treated with CSII or MDI (not degludec)

Exclusion criteria:
  • BMI < 20 or > 30 kg/m2

  • BMI z-score <5th or >95th percentile

  • Celiac disease

  • Pregnancy

  • Smoking

  • Reported history of illicit substance use

  • History of active cardiovascular, cerebrovascular, or peripheral vascular disease

  • Active renal disease evidenced by estimated GFR < 50 mL/min/1.73 m2

  • History of traumatic brain injury

  • Dementia or any other neurologic disease

  • Psychiatric disease\

  • Any learning disability

  • Hemoglobin A1c > 8.5%

  • Hemoglobin A1c > 9%

  • T2DM, or impaired fasting glucose

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic in Rochester Rochester Minnesota United States 55905

Sponsors and Collaborators

  • Mayo Clinic

Investigators

  • Principal Investigator: K Sreekumaran Nair, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
K. Sreekumaran Nair, Consultant Endocrinology and Metabolism, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT03392441
Other Study ID Numbers:
  • 17-005244
First Posted:
Jan 8, 2018
Last Update Posted:
Feb 3, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by K. Sreekumaran Nair, Consultant Endocrinology and Metabolism, Mayo Clinic
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 3, 2022